What is ABUS's health score?

Arbutus Biopharma Corp (ABUS) has a TradeApes health score of 60 out of 100, rated Healthy. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is ABUS's estimated fair value?

Based on our 5-year discounted cash flow model, Arbutus Biopharma Corp's estimated fair value is $N/A per share. This is a model estimate, not a price target or investment recommendation.

Is ABUS undervalued or overvalued?

Our model currently rates ABUS as Inconclusive. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

To Unlock Full Report

2 free score cards remaining

Arbutus Biopharma Corp (ABUS)

Healthcare Inconclusive inconclusive healthy

$4.41

Updated: 2026-07-21

TradeApes Score

Financial Strength

55 Mixed

Operating Trend

60 Healthy

Relative Value

58 Mixed

Capital Allocation

55 Mixed

Risk Management

80 Strong

Key Findings

+ Net cash position — more cash on hand than total debt

Unlock Full Report →

− Large FCF burn — cash consumption exceeds 10% of revenue

Unlock Full Report →

Industry Related Stocks

ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) Aardvark Therapeutics, Inc. (AARD) Abivax S.A. (AAVXF) Ascend Wellness Holdings, Inc. (AAWH) AbbVie Inc. (ABBV) AbCellera Biologics Inc. (ABCL)

See all Healthcare stocks →

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.